sumatriptan has been researched along with ketorolac in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (9.52) | 18.2507 |
2000's | 8 (38.10) | 29.6817 |
2010's | 8 (38.10) | 24.3611 |
2020's | 3 (14.29) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Kumar, KL | 1 |
Landy, S; Lobo, BL | 1 |
Benedetti, F; Lanotte, M; Lopiano, L; Pollo, A; Rainero, I; Vighetti, S | 1 |
Brewer, KL; Meredith, JT; Wait, S | 1 |
Berger, MY; Bruijn, JK; Damen, L; Koes, BW; Passchier, J; Verhagen, AP | 1 |
Keller, DL | 1 |
Dash, PD; Gelaye, B; Kurth, T; Nitchie, H; Peterlin, BL; Rao, AS | 1 |
Al-Karagholi, MA; Amin, FM; Arngrim, N; Ashina, M; Ghanizada, H; Larsson, HBW; Metcalf-Clausen, M; Mørch-Rasmussen, M | 1 |
Abu Bakar, MA; Baharuddin, KA; Norhayati, MN; Nurathirah, MN; Yazid, MB | 1 |
Abd-ElGawad, M; Abdelhay, HM; Abdelmonem, H; Abdelwadoud, GT; Ahmed, AE; Al-Dardery, NM; Alhosini, ANM; Kamel, MA; Mohamed, SW | 1 |
5 review(s) available for sumatriptan and ketorolac
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent advances in the acute management of migraine and cluster headaches.
Topics: Analgesics; Butorphanol; Capsaicin; Cluster Headache; Dihydroergotamine; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Sumatriptan; Tolmetin | 1994 |
Symptomatic treatment of migraine in children: a systematic review of medication trials.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Controlled Clinical Trials as Topic; Dihydroergotamine; Female; Humans; Ibuprofen; Ketorolac; Male; Migraine Disorders; Prochlorperazine; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan | 2005 |
Efficacy of ketorolac in the treatment of acute migraine attack: A systematic review and meta-analysis.
Topics: Caffeine; Dexamethasone; Diclofenac; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Pain; Phenothiazines; Sumatriptan; Valproic Acid | 2022 |
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Chlorpromazine; Granisetron; Headache; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Nausea; Network Meta-Analysis; Prochlorperazine; Randomized Controlled Trials as Topic; Sumatriptan; Valproic Acid | 2023 |
4 trial(s) available for sumatriptan and ketorolac
Article | Year |
---|---|
Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses.
Topics: Aged; Analgesia; Attitude to Health; Cognition; Conditioning, Operant; Consciousness; Female; Human Growth Hormone; Humans; Hydrocortisone; Ketorolac; Male; Middle Aged; Motor Skills; Pain; Parkinson Disease; Placebo Effect; Subthalamic Nucleus; Sumatriptan; Unconsciousness | 2003 |
A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine.
Topics: Administration, Intranasal; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Humans; Infusions, Intravenous; Ketorolac; Male; Middle Aged; Migraine Disorders; Pain Measurement; Prospective Studies; Sumatriptan; Treatment Outcome; Vasoconstrictor Agents | 2003 |
A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Hyperalgesia; Ketorolac; Male; Middle Aged; Migraine Disorders; Nasal Absorption; Pain Threshold; Serotonin 5-HT1 Receptor Agonists; Sumatriptan; Surveys and Questionnaires; Treatment Outcome | 2016 |
Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Double-Blind Method; Female; Headache; Humans; Infusions, Intravenous; Ketorolac; Magnetic Resonance Angiography; Male; Models, Theoretical; Pain Measurement; Pituitary Adenylate Cyclase-Activating Polypeptide; Serotonin 5-HT1 Receptor Agonists; Sumatriptan; Vasodilator Agents | 2020 |
12 other study(ies) available for sumatriptan and ketorolac
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Recommendations for the emergency treatment of migraine headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Dexamethasone; Dihydroergotamine; Emergency Medical Services; Humans; Ketorolac; Migraine Disorders; Sumatriptan; Tolmetin | 1994 |
Triptan therapy in migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Indomethacin; Injections, Intravenous; Ketorolac; Migraine Disorders; Sumatriptan; United States; Vasoconstrictor Agents | 2010 |